The multidisciplinary LYMIT-DIS project integrates recent technological and conceptual advances developed by the scientific participants, including metabolomic analyses as well as in-patient evaluations of microvascular function to develop innovative therapies for patients with diastolic heart failure.
LYMIT-DIS addresses the ERA‐Net Cofund action (European Research Area Network co-funded by the European Commission, EC) under the ‘ERA-CVD mission: “create a European Research Area in which cardiovascular research is conducted and funded across countries, allowing research groups to jointly work on specific problems, exchange ideas, and benefit from cross border expertise”. The goal of ERA-CVD is to create a European Research Area in which cardiovascular research is conducted and funded across countries via the responsible funding organisations, allowing research groups to jointly work on specific challenges, exchange ideas, and benefit from cross border expertise.
LYMIT-DIS brings together universities and research institutions to employ knowledge of cardiac blood vessels and lymphatics, cardiac metabolism and regulation of fibrosis to develop innovative therapeutic , preventive, and diagnostic strategies for diastolic heart failure.
This project has received funding from the EU Framework Programme for Research and Innovation ‘Horizon 2020’ through the ERA-CVD program co-funded by the European Commission under National Grant agreement numbers: ANR-16-ECVD-0004, NWO-ZonMw 2016T091, FWO-G0H7716N, AC16/00020
Publications emanating from the LYMIT-DIS project: